ArticleCancers2025

Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit.

Takuto Ogasawara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.